• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Wednesday, May 31, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Science

First multicenter trial; CAR T-cell immunotherapy effective for lymphoma

Bioengineer by Bioengineer
December 6, 2016
in Science
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

(San Diego, December 6, 2016) – A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings. The study, which involved 22 institutions and tested a product called KTE-C19 (anti-CD19 CAR), is the first multicenter trial of this cellular immunotherapy-based treatment approach for lymphoma.

The study focuses on patients with aggressive non-Hodgkin lymphoma that does not respond to chemotherapy or recurs after autologous stem cell transplant. Such chemorefractory patients have a poor prognosis; median overall survival is just over six months and only about eight percent achieve complete cancer remission with existing therapies. The experimental therapy, KTE-C19, is designed to equip a patient's own immune cells with weapons to find and destroy cancer cells.

"Patients with aggressive non-Hodgkin lymphoma have a major unmet need in terms of available therapies that can induce long-term remission, and there really has been no new treatment for these patients for over 20 years," said lead study author Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center in Houston. "KTE-C19 could potentially be the solution to that need, and the hope is that this treatment option could be curative for some of these patients."

He said the study, called ZUMA-1, bolsters evidence from previous trials that reported sustained remission after CAR T-cell therapy with KTE-C19, a treatment in which doctors extract T cells from a patient, genetically engineer the cells with CD19 receptors to seek out cancer cells, expand the population of the engineered cells, and then infuse them back into the patient. In the first phase of ZUMA-1, which was conducted in four institutions, 43 percent of patients have ongoing complete remission at 12 months.

To test the treatment's real-world feasibility, the second phase of ZUMA-1 expanded the study to involve 22 institutions, most of which had no prior experience with CAR T-cell therapy. The new findings report positive results from a pre-specified interim analysis of 51 patients with diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of non-Hodgkin lymphoma. Following KTE-C19 treatment, these patients had an overall response rate of 76 percent (47% complete remission and 29% partial remission) with most responses noted within the first month. As in previous studies, some patients' cancers rebounded after the first few months; by the end of month three, the overall remission rate was 39 percent (33% complete remission and 6% partial remission).

Researchers said the results are encouraging from an efficacy standpoint and also show that CAR T-cell manufacturing, treatment logistics, and the management of adverse events can be successfully implemented across multiple sites. "Efficacy often tends to be lower when you apply a new treatment at multiple centers," said Dr. Neelapu. "It was very gratifying to see that efficacy and side effects are similar to what was observed in previous single-institution studies."

Serious adverse events reported in the total DLBCL cohort of 73 patients that were related to KTE-C19 included neurologic events (25% of patients; typically temporary confusion or disorientation) and grade three or higher cytokine release syndrome, a common, potentially dangerous reaction to this type of infusion (14% of patients). The most common symptoms of cytokine release syndrome were fever, drop in blood pressure, and shortness of breath, according to Dr. Neelapu. Researchers report one patient died as a result of over-activation of the immune system.

Recent studies of CAR T-cell therapy have improved the ability to manage side effects, researchers said. "We now have guidelines on how to recognize and grade these side effects and how to manage the symptoms, and we were able to implement those across multiple institutions with no prior experience with CAR T-cell therapy," said Dr. Neelapu. "I think it has become much more manageable and safer now."

The team has also separately analyzed results from 20 patients in ZUMA-1's second cohort (abstract #998), which include patients with primary mediastinal B-cell lymphoma or transformed follicular lymphoma, two tumor types that are less common than DLBCL. The overall response rate in this second cohort is 80 percent with a complete remission rate of 55 percent. The researchers will continue to track patient outcomes in these cohorts for 15 years.

###

The study was funded by Kite Pharma, Inc., which makes KTE-C19 and partially supported by The Leukemia & Lymphoma Society Therapy Acceleration ProgramĀ®.

Sattva S. Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, will present this study, titled "Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1," (LBA-6) during the late-breaking abstracts session on Tuesday, December 6 at 7:30 a.m. PST in Hall AB.

For the complete annual meeting program and abstracts, visit http://www.hematology.org/annual-meeting. Follow @ASH_hematology and #ASH16 on Twitter and like ASH on Facebook for the most up-to-date information about the 2016 ASH Annual Meeting.

The American Society of Hematology (ASH) (http://www.hematology.org) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood (http://www.bloodjournal.org), the most cited peer-reviewed publication in the field, as well as the newly launched, online, open-access journal, Blood Advances (http://www.bloodadvances.org).

Media Contact

Stephen Fitzmaurice
[email protected]
561-506-6890
@Bloodjournal

http://www.hematology.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Five or more hours of smartphone usage per day may increase obesity

July 25, 2019
IMAGE

NASA’s terra satellite finds tropical storm 07W’s strength on the side

July 25, 2019

NASA finds one burst of energy in weakening Depression Dalila

July 25, 2019

Researcher’s innovative flood mapping helps water and emergency management officials

July 25, 2019
Please login to join discussion

POPULAR NEWS

  • plants

    Plants remove cancer causing toxins from air

    39 shares
    Share 16 Tweet 10
  • Element creation in the lab deepens understanding of surface explosions on neutron stars

    36 shares
    Share 14 Tweet 9
  • Groundbreaking study uncovers first evidence of long-term directionality in the origination of human mutation, fundamentally challenging Neo-Darwinism

    115 shares
    Share 46 Tweet 29
  • How life and geology worked together to forge Earth’s nutrient rich crust

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Biological cleanup discovered for certain ā€œforever chemicalsā€

The clams that fell behind, and what they can tell us about evolution and extinction

Shedding light on the complex flow dynamics within the small intestine

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 50 other subscribers
  • Contact Us

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org Ā© Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In